N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics in vitro / ex vivo

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1987

Reliability:

1 (reliable without restriction)

Data source

Reference

Reference Type:

other: Body responsible for the test

Title:

Unnamed

Year:

1987

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 417 (Toxicokinetics)

GLP compliance:

yes

Test material

Test material information

Constituent 1

Reference substance name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

EC Number:

401-990-0

EC Name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Cas Number:

106990-43-6

Molecular formula:

C132H250N32

IUPAC Name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Constituent 2

Reference substance name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino) triazin-2-yl)-4,7-diazadecane-1,10-diamine

IUPAC Name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino) triazin-2-yl)-4,7-diazadecane-1,10-diamine

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

Radiolabelling:

yes

Test animals

Species:

rat

Strain:

not specified

Sex:

male

Administration / exposure

Route of administration:

oral: unspecified

Vehicle:

corn oil

Details on exposure:

Method of administration or exposure: a single dose via oral gavage

No. of animals per sex per dose / concentration:

Male: 4 animals at CA 50mg/kg
Male: 4 animals at CA 1000 mg/kg

Details on study design:

Objective of study: The purpose of this study is to obtain information on the absorption, distribution and excretion (ADE) of [14C-]Chimassorb 119 in the male rat. The study was also performed to determine and compare the ADE patterns of [14C-]Chimassorb 119 as a function of oral dosege level.
This information may be used as an aid in the evaluation and interpretation of other toxicology studies and the study results may contribute to provide a rational basis for toxicological risk assessment in man.

Results and discussion

Metabolite characterisation studies

Details on metabolites:

After oral dose of 50 and 1000 mg of [14C-]Chimassorb 119 per kg body weight, the excretion of total radioactivity in virtually complete within 96 hours after administration, radioactivity is excreted nearly entirely via faeces (96-99% of recovered radiolabel).
Renal excretion is very low (0.28 - 0.60% of the dose), and excretion of radioactivity via expired air negligible (<= 0.01% of the dose). There is hardly any retention of radioactivity in tissues. There was no significant bioconcentration or accumulation in any of the organs investigated.